American Journal of Kidney Diseases
Volume 52, Issue 4 , Pages 649-652 , October 2008

Dialysis Dosing in Critically Ill Patients With Acute Kidney Injury

  • H. David Humes, MD

      Affiliations

    • University of Michigan School of Medicine, Ann Arbor, Michigan
    • Corresponding Author InformationAddress correspondence to H. David Humes, MD, Division of Nephrology, Department of Internal Medicine, University of Michigan School of Medicine, 4520 MSRB I, SPC 5651, 1150 W Medical Center Dr, Ann Arbor, MI 48109
    • ,
  • Feng Ding, MD

      Affiliations

    • Fudan University, Huashan Hospital, Shanghai, China
    • ,
  • Joon Ho Song, MD

      Affiliations

    • Inha University School of Medicine, Incheon, Korea

References 

  1. Burton B. Overview of end stage renal disease. J Dial. 1976;1:1–23
  2. Lameire N, Van Biesen W, Vanholder R. The rise of prevalence and the fall of mortality of patients with acute renal failure: what the analysis of two databases does and does not tell us. J Am Soc Nephrol. 2006;17:923–925
  3. The Albert Lasker Award for Clinical Medical Research. Kidney Int. 2002;62:1915–1918
  4. Pannu N, Klarenbach S, Wiebe N. Renal replacement therapy in patients with acute renal failure: a systematic review. JAMA. 2008;299:793–805
  5. Palevsky PM, Zhang JH, O'Connor TZ, et al. VA/NIH Acute Renal Failure Trial Network: Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008;359:7–20
  6. Eknoyan G, Beck G, Cheung A, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347:2010–2019
  7. Bellomo R. Do we know the optimal dose for renal replacement therapy in the intensive care unit?. Kidney Int. 2005;70:1202–1204
  8. Schiffl H, Lang SM, Fischer R. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med. 2002;346:309–310
  9. Saudan P, Niederberger M, De Seigneux S. Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. Kidney Int. 2006;70:1312–1317
  10. Tolwani A, Campbell R, Stofan B, Lai KR, Oster RA, Wille KM. Standard versus high-dose CVVHDF for ICU-related acute renal failure. J Am Soc Nephrol. 2008;19:1233–1238
  11. Bouman CS, Oudemans-Van Straaten HM, Tijssen JG, Zandstra DF, Kesecioglu J. Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: A prospective, randomized trial. Crit Care Med. 2002;30:2205–2211
  12. Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomized trial. Lancet. 2000;356:26–30
  13. Waikar S, Liu K, Chertow G. Diagnosis, epidemiology and outcomes of acute kidney injury. Clin J Am Soc Nephrol. 2008;3:844–861
  14. Imai E, Iwatani H. The continuing story of renal repair with stem cells. J Am Soc Nephrol. 2007;18:2423–2428
  15. Wolfe RA. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341:1725–1730
  16. Tumlin J, Wali R, Williams W, et al. Efficacy and safety of renal tubule cell therapy for acute renal failure. J Am Soc Nephrol. 2008;19:1034–1040
  17. Simmons EM, Himmelfarb J, Sezer MT, et al. Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int. 2004;65:1357–1365
  18. Okusa MD. The inflammatory cascade in acute ischemic renal failure. Nephron. 2002;90:133–138
  19. Maroszynska I, Fiedor P. Leukocytes and endothelium interaction as rate limiting step in the inflammatory response and a key factor in the ischemia-reperfusion injury. Ann Transplant. 2000;5:5–11
  20. Ding F, Song JH, Lou L, et al: A novel selective cytopheretic inhibitory device (SCD) inhibits circulating leukocyte activation and ameliorates multiorgan dysfunction in a porcine model of septic shock. J Am Soc Nephrol (abstr) (in press)
  21. Humes HD, Dillon J, Tolwani A, et al: A novel selective cytopheretic inhibitory device (SCD) improves mortality in ICU patients with acute kidney injury (AKI) and multiorgan failure (MOF) in a phase II clinical study. J Am Soc Nephrol (abstr) (in press)

PII: S0272-6386(08)01236-5

doi: 10.1053/j.ajkd.2008.07.033

American Journal of Kidney Diseases
Volume 52, Issue 4 , Pages 649-652 , October 2008

Article Tools